Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
BioLine Rx Analyst Ratings and Price Targets | NASDAQ:BLRX | Benzinga
BioLine Rx Ltd has a consensus price target of $15 based on the ratings of 3 analysts. The high is $26 issued by HC Wainwright & Co. on March 31, 2025. The low is $4 issued by Oppenheimer on May 25, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 31, 2025, November 25, 2024, and November 6, 2024, respectively. With an average price target of $18.67 between HC Wainwright & Co., there's an implied 604.40% upside for BioLine Rx Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for BioLine Rx
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | — | Jones Trading | Justin Walsh40% | — | Downgrade | Buy → Hold | Get Alert |
| 03/31/2025 | Buy Now | 881.13% | HC Wainwright & Co. | Joseph Pantginis43% | $9 → $26 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | 239.62% | HC Wainwright & Co. | Joseph Pantginis43% | $840 → $360 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 692.45% | HC Wainwright & Co. | Joseph Pantginis43% | $840 → $840 | Reiterates | Buy → Buy | Get Alert |
| 09/04/2024 | Buy Now | -24.53% | Jones Trading | Justin Walsh40% | → $80 | Initiates | → Buy | Get Alert |
| 06/03/2024 | Buy Now | 692.45% | HC Wainwright & Co. | Joseph Pantginis43% | $840 → $840 | Reiterates | Buy → Buy | Get Alert |
| 05/29/2024 | Buy Now | 692.45% | HC Wainwright & Co. | Joseph Pantginis43% | $840 → $840 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 692.45% | HC Wainwright & Co. | Joseph Pantginis43% | $840 → $840 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2024 | Buy Now | 692.45% | HC Wainwright & Co. | Joseph Pantginis43% | $840 → $840 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 692.45% | HC Wainwright & Co. | Joseph Pantginis43% | $840 → $840 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | Buy Now | 692.45% | HC Wainwright & Co. | Joseph Pantginis43% | $840 → $840 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 692.45% | HC Wainwright & Co. | Joseph Pantginis43% | $760 → $840 | Maintains | Buy | Get Alert |
| 08/31/2023 | Buy Now | 616.98% | HC Wainwright & Co. | Joseph Pantginis43% | → $760 | Reiterates | Buy → Buy | Get Alert |
| 05/25/2023 | Buy Now | 50.94% | Oppenheimer | Mark Breidenbach48% | → $160 | Reiterates | → Outperform | Get Alert |
FAQ
What is the target price for BioLine Rx (BLRX) stock?
The latest price target for BioLine Rx (NASDAQ:BLRX) was reported by Jones Trading on April 2, 2025. The analyst firm set a price target for $0.00 expecting BLRX to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioLine Rx (BLRX)?
The latest analyst rating for BioLine Rx (NASDAQ:BLRX) was provided by Jones Trading, and BioLine Rx downgraded their hold rating.
When was the last upgrade for BioLine Rx (BLRX)?
There is no last upgrade for BioLine Rx
When was the last downgrade for BioLine Rx (BLRX)?
The last downgrade for BioLine Rx Ltd happened on April 2, 2025 when Jones Trading changed their price target from N/A to N/A for BioLine Rx Ltd.
When is the next analyst rating going to be posted or updated for BioLine Rx (BLRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLine Rx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLine Rx was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating BioLine Rx (BLRX) correct?
While ratings are subjective and will change, the latest BioLine Rx (BLRX) rating was a downgraded with a price target of $0.00 to $0.00. The current price BioLine Rx (BLRX) is trading at is $2.77, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.